论文部分内容阅读
目的研究布加综合征(BCS)患者凝血因子V Leiden突变(FVLeiden)及凝血酶原基因G20210A突变(FⅡG20210A)的情况及其与BCS发病的相关性。方法利用聚合酶链反应-限制性片段长度多态性分析法(PCR-RFLP)对比检测49例BCS患者及70例健康对照者FVLeiden及 FⅡG20210A突变情况。结果 45例中国汉族散发性BCS患者、两对家族性BCS患者及70例汉族健康对照个体未发现有F V Leiden及F ⅡG20210A突变。结论我国汉族BCS患者未发生 FVLeiden及FⅡG20210A突变,BCS的发病与FVLeiden及FⅡG20210A突变无相关性。
Objective To investigate the relationship between FVLeiden and prothrombin G20210A mutation (FⅡG20210A) in patients with Budd-Chiari syndrome (BCS) and their association with the pathogenesis of BCS. Methods The mutations of FVLeiden and FⅡG20210A in 49 BCS patients and 70 healthy controls were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results FV Leiden and F ⅡG20210A mutations were found in 45 Chinese Han sporadic BCS patients, two pairs of familial BCS patients and 70 Han healthy controls. Conclusion There is no FV Leiden and FⅡG20210A mutations in Chinese Han patients with BCS. The incidence of BCS is not related to the FV Leiden and F Ⅱ G20210A mutations.